New drug trial aims to shrink dangerous heart plaque
NCT ID NCT07293260
Summary
This study is testing whether a drug called olpasiran can reduce the amount of soft, dangerous plaque in the heart arteries of people who already have heart disease and high levels of a specific blood fat called lipoprotein(a). About 406 participants will receive either olpasiran or a placebo (inactive substance) for 72 weeks, and doctors will use special heart scans to measure changes in plaque. The main goal is to see if the drug safely lowers plaque volume to help control heart disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.